Citation Tools

PDF

Extended report
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Download to a citation manager

Cite this article as:
Burmester GR, McInnes IB, Kremer J on behalf of the EARTH EXPLORER 1 study investigators, et al
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis